ArticleJournal of nanobiotechnology2010
Mode of antiviral action of silver nanoparticles against HIV-1.
Article in Journal of nanobiotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 281 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
281 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,054 citations in OpenAlex.
- A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.Life sciences · 2020Pooled it
- Integrating silver nanomaterials in wound healing: from physicochemical properties to clinical translation.Journal of nanobiotechnology · 2026Review
- Nano-Silver-Selenium Liquid Dressing Facilitates Treatment of Monkeypox and Prevention of Viral Transmission in a Surrogate Mouse Model.Exploration (Beijing, China) · 2026Article
- Repurposing CNS drugs Zonisamide and Perampanel conjugated with silver nanoparticles as an anti-amoebic agent in combating Granulomatous Amebic Encephalitis (GAE) and Primary Amebic Meningoencephalitis (PAM) infection caused byParasite epidemiology and control · 2026Article
- Gellan Gum/Alginate Films Containing BiogenicMolecules (Basel, Switzerland) · 2026Article
- Metallic nanoparticles: from biosynthesis to biomedical applications, current scenarios and prospects.Nanoscale advances · 2026Review
- Nanoparticle delivery systems for HIV pre-exposure prophylaxis (PrEP): advances and challenges.Beilstein journal of nanotechnology · 2026Review
- Characterization of Normal and Ozone StressedFood science & nutrition · 2025Article
- Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review).International journal of molecular medicine · 2025Review
- Synthesis of new Ag(i) and Cd(ii) hydrozanomide-based complexes with antibacterial and anticancer properties.RSC advances · 2025Article
- Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics.Advanced healthcare materials · 2025Review
- Silver Nanoparticle-Mediated Antiviral Efficacy against Enveloped Viruses: A Comprehensive Review.Global challenges (Hoboken, NJ) · 2025Review
- Silver Nanoparticles (AgNPs) as Potential Antiviral Agents: Synthesis, Biophysical Properties, Safety, Challenges and Future Directions─Update Review.Molecules (Basel, Switzerland) · 2025Review
- Antimicrobial Activity of Poly(methyl methacrylate) Doped with CuO and ZnO Nanoparticles.ACS omega · 2025Article
- Nonwoven fabric coated with cerium oxide nanoparticles for viral inactivation and transmission Inhibition.Scientific reports · 2025Article
- Advanced Nanomaterials for Cancer Therapy: Gold, Silver, and Iron Oxide Nanoparticles in Oncological Applications.Advanced healthcare materials · 2025Review
- Silver Nanoparticles-Functionalized Textile against SARS-CoV-2: Antiviral Activity of the Capping Oleylamine Molecule.ACS applied materials & interfaces · 2025Article
- Staphylococcal Drug Resistance: Mechanisms, Therapies, and Nanoparticle Interventions.Infection and drug resistance · 2025Review
- Nanoagent-Mediated Photothermal Therapy: From Delivery System Design to Synergistic Theranostic Applications.International journal of nanomedicine · 2025Review
- Review
221 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSilver nanoparticles have proven to exert antiviral activity against HIV-1 at non-cytotoxic concentrations, but the mechanism underlying their HIV-inhibitory activity has not been not fully elucidated. In this study, silver nanoparticles are evaluated to elucidate their mode of antiviral action against HIV-1 using a panel of different in vitro assays.
resultsOur data suggest that silver nanoparticles exert anti-HIV activity at an early stage of viral replication, most likely as a virucidal agent or as an inhibitor of viral entry. Silver nanoparticles bind to gp120 in a manner that prevents CD4-dependent virion binding, fusion, and infectivity, acting as an effective virucidal agent against cell-free virus (laboratory strains, clinical isolates, T and M tropic strains, and resistant strains) and cell-associated virus. Besides, silver nanoparticles inhibit post-entry stages of the HIV-1 life cycle.
conclusionsThese properties make them a broad-spectrum agent not prone to inducing resistance that could be used preventively against a wide variety of circulating HIV-1 strains.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.